TME Pharma: Net Loss Reduced to €3.3M in 2025
TME Pharma released its annual 2025 results on Thursday, showing an improvement in its net loss, which fell to €3.3 million from €5.7 million the previous year. This improvement reflects the effects of the restructuring in June 2025, which reduced costs through outsourcing functions. However, the company's equity turned negative at -€1.6 million, while cash reserves remained limited to €2 million as of December 31, 2025.
Net Loss Reduced Due to Restructuring
TME Pharma's net loss contracted to €3.3 million in 2025, a significant decrease from the €5.7 million recorded in 2024. This improvement directly results from the organizational transformation implemented in June 2025, which involved adopting a virtual company structure that minimized costs through the near-total outsourcing of functions related to programs and partnership relations. This restructuring is part of a broader strategic redefinition of the group, now led by Diede van den Ouden, the new CEO who took office in June 2025, aiming to enhance its two main assets: NOX-A12 and NOX-E36.
Negative Equity and Fragile Cash Flow
Despite operational improvement, TME Pharma's financial situation deteriorated on the balance sheet. Equity is now negative at -€1.6 million as of December 31, 2025, compared to a positive position of €1.6 million a year earlier. Available cash was at €2 million at the end of the 2025 fiscal year. In March 2026, however, the group announced it had secured a 12-month extension on loan maturities taken out in May and August 2025, thus extending financial visibility until the second quarter of 2027. This extension is based on agreements with certain lenders and considers the current level of activity of the biotech.
Pursuit of Partnerships and Lack of Revenue
TME Pharma continues to generate zero commercial revenue, as in each previous year. The group does not anticipate any revenue until its candidate products have secured licensing agreements, regulatory approvals, or collaboration agreements with third parties. For 2026, the company is focusing its efforts on securing licensing agreements or strategic partnerships involving NOX-A12 and NOX-E36. It is also exploring other revenue sources and activities, as well as financing and partnership solutions. Any major development resulting from this new strategy will be subject to shareholder approval and will be announced via press releases.
